It is imperative that health care practitioners and researchers from disparate disciplines collectively focus efforts to appropriately develop gender-specific evidence-based guidelines for bladder cancer patients. We must strive to develop multidisciplinary collaborative efforts to provide tailored gender-specific care for bladder cancer patients.

Following the introduction of prostate-specific antigen (PSA) screening in the early 1990s, there has been a 50% decline in prostate cancer-specific mortality and more than a 70% decline in the incidence of metastases at diagnosis. 1 Given the recent declines in PSA screening and prostate cancer incidence, we sought to assess the effect of these changes on prostate cancer presentation.Methods | Using the most recent Surveillance, Epidemiology, and End Results (SEER) release, we identified 1 107 111 men 40 years or older diagnosed with pathologically confirmed prostate cancer and 545 399 from 2004 to 2013. Temporal variations in cancer characteristics and PSA (available for 2010-2013) were assessed using the Cochrane-Armitage test for categorical variables and Jonckheere-Terpstra test for PSA. Analysis was stratified by age (<75 vs ≥75 years). Incidence of distant metastasis was derived quarterly with SEER Collaborative staging. After standardization to the 2000 US census, restricted cubic spline model with 4 knots was used to examine temporal variation in incidence. Detailed statistical methods and SAS data